Lung adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lung adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Durvalumab compared with standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer https://clinicaltrials.eu/trial/durvalumab-with-drug-combination-versus-standard-chemotherapy-in-elderly-patients-with-advanced-non-small-cell-lung-cancer/ Thu, 18 Jun 2026 04:08:13 +0000 https://clinicaltrials.eu/trial/durvalumab-with-drug-combination-versus-standard-chemotherapy-in-elderly-patients-with-advanced-non-small-cell-lung-cancer/ The trial focuses on older adults with advanced NSCLC, a type of lung cancer that is not the small‑cell form. It compares an immunotherapy drug called durvalumab with the usual chemotherapy regimen that may include medicines such as vinorelbine, pemetrexed, carboplatin, cisplatin, paclitaxel or gemcitabine. Participants must have a tumor‑expressed protein level of PDL1 ≥ 25% or an unknown level, which can influence how well the immune‑based treatment works.

The purpose of the study is to see whether giving the immune‑based drug first, and switching to standard drug treatment if the cancer progresses, works better than the opposite order. Patients are randomly assigned to one of the two sequences, receive the medicines by IV infusion every few weeks, and are followed for at least a year. During the follow‑up, researchers look at how many participants are still alive after 12 months (a measure called overall survival) and how many die within the first four months after starting treatment, while also monitoring side effects and quality of life.

]]> Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein https://clinicaltrials.eu/trial/study-of-bemarituzumab-treatment-for-patients-with-solid-tumors-that-have-high-levels-of-fgfr2b-protein/ Wed, 29 Apr 2026 15:07:15 +0000 https://clinicaltrials.eu/trial/study-of-bemarituzumab-treatment-for-patients-with-solid-tumors-that-have-high-levels-of-fgfr2b-protein/ This study focuses on various types of solid tumors that have a specific characteristic called FGFR2b overexpression. The types of cancer being studied include head and neck squamous cell carcinoma, triple-negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, ovarian epithelial carcinoma, endometrial adenocarcinoma, and cervical carcinoma. The treatment being tested is a medicine called bemarituzumab (also known as AMG 552), which is given through an intravenous infusion directly into the bloodstream.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

]]> Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer https://clinicaltrials.eu/trial/study-on-bi-907828-for-patients-with-advanced-biliary-tract-pancreatic-lung-or-bladder-cancer/ Wed, 29 Apr 2026 14:26:22 +0000 https://clinicaltrials.eu/trial/study-on-bi-907828-for-patients-with-advanced-biliary-tract-pancreatic-lung-or-bladder-cancer/ This clinical trial is focused on studying the effects of a new treatment called BI 907828 on certain types of cancer. The cancers being studied include biliary tract cancer, which affects the bile ducts, gallbladder, and ampulla of Vater; pancreatic cancer, specifically pancreatic ductal adenocarcinoma; lung cancer, specifically lung adenocarcinoma; and bladder cancer, specifically urothelial bladder cancer. These cancers are known to be locally advanced or have spread to other parts of the body, making them challenging to treat with standard therapies.

The purpose of this study is to evaluate how effective and safe BI 907828 is when used alone in treating these cancers. The study will involve patients who have specific genetic characteristics, such as MDM2 amplification and TP53 wild-type status, which are important for the treatment to potentially work. Participants will take the medication in the form of a film-coated tablet by mouth. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, patients will be closely observed to assess the treatment’s impact on their cancer and overall health. The study aims to gather information on how long the treatment can control the disease, how long patients live after starting the treatment, and any changes in their quality of life. This information will help determine if BI 907828 could be a beneficial treatment option for these types of cancer in the future.

]]> Study Comparing Atezolizumab and Drug Combination with Pembrolizumab and Drug Combination for Patients with Advanced Lung Cancer https://clinicaltrials.eu/trial/study-comparing-atezolizumab-and-drug-combination-with-pembrolizumab-and-drug-combination-for-patients-with-advanced-lung-cancer/ Wed, 29 Apr 2026 14:23:55 +0000 https://clinicaltrials.eu/trial/study-comparing-atezolizumab-and-drug-combination-with-pembrolizumab-and-drug-combination-for-patients-with-advanced-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as metastatic TTF-1 negative lung adenocarcinoma. The study aims to compare the effectiveness of two different treatment combinations. The first treatment group will receive a combination of atezolizumab, carboplatin, and nab-paclitaxel. The second treatment group will receive pembrolizumab, a type of platinum-based drug, and pemetrexed. These medications are given as solutions through a vein, a method known as intravenous infusion.

The purpose of the study is to compare the survival rates of patients receiving these different treatment combinations. Participants in the study will receive their assigned treatment over a period of up to 12 months. During this time, they will have regular hospital visits for treatment and follow-up examinations to monitor their health and the effects of the treatment.

By participating in this study, researchers hope to gather valuable information that could improve treatment options for patients with this specific type of lung cancer. The study will help determine which combination of medications might offer better outcomes for patients in terms of survival. The results of this study could potentially lead to advancements in the treatment of metastatic TTF-1 negative lung adenocarcinoma.

]]>